Bersiporocin

N/A

Report date: 2025/03/31 16:54:18
NMEFirst In Class

Base Information

Drug NameBersiporocin
Drug Alias NameBersipososinDWN-12088ODP-2301CSP-088
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionAminoacyl-tRNA synthetase inhibitors
TargetsAminoacyl-tRNA synthetase
Therapy Area/IndicationsScleroderma, SystemicKeloidDiabetic Nephropathies +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesSouth Korea
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesDaewoong Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesOncocross Co LtdCS Pharmaceuticals LtdDaewoong Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsScleroderma, SystemicKeloidDiabetic Nephropathies +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A